<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03393611</url>
  </required_header>
  <id_info>
    <org_study_id>1107011830</org_study_id>
    <nct_id>NCT03393611</nct_id>
  </id_info>
  <brief_title>CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome</brief_title>
  <official_title>A Pilot Study of a Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by Allogeneic Stem-Cell Transplantation (SCT) Utilizing a Haplo-cord Graft for Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is designed to evaluate outcomes with the combination of CPX-351 salvage
      therapy and haplo-cord graft stem cell transplantation for subjects with relapsed or
      refractory AML or myelodysplastic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2012</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutrophil Engraftment</measure>
    <time_frame>100 days</time_frame>
    <description>Evaluate the time to neutrophil engraftment, defined as the first day in which absolute neutrophil count (ANC) &gt;500/mm3 for three consecutive days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival at Day 100, 6 months, and 1 year</measure>
    <time_frame>Day 100, 6 months, and 1 year post-transplant</time_frame>
    <description>Evaluate survival of subjects alive, with or without presence of disease, at the designated time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-Free Survival at Day 100, 6 months, and 1 year</measure>
    <time_frame>Day 100, 6 months, and 1 year post-transplant</time_frame>
    <description>Evaluate survival of subjects alive without disease at the designated time points</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-Relapse Mortality</measure>
    <time_frame>Day 100</time_frame>
    <description>Death that cannot be explained by persistence, relapse, or progression of underlying disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Rate</measure>
    <time_frame>Day 100, 6 months, 1 year</time_frame>
    <description>Time to first relapse or progression of underlying disease after initiation of protocol therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Leukemia, Relapsed Adult Acute Myeloid</condition>
  <condition>Myelodysplastic Syndromes, Previously Treated</condition>
  <arm_group>
    <arm_group_label>CPX-351 Salvage Therapy and Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive CPX-351 salvage chemotherapy on Day -21, -19, and -17 as a bridge to allogeneic stem cell transplantation using a Fludarabine/Melphalan/rATG conditioning regimen and a haplo-cord graft.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-351</intervention_name>
    <description>Salvage Chemotherapy: CPX-351 at 120 u/m2 on Days -21, -19, and -17</description>
    <arm_group_label>CPX-351 Salvage Therapy and Transplant</arm_group_label>
    <other_name>Cytarabine:Daunorubicin Liposome Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 150 mg/m2 (30 mg/m2/day x 5 days, Day -7 to Day -3)</description>
    <arm_group_label>CPX-351 Salvage Therapy and Transplant</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan 140 mg/m2 (Day -2)</description>
    <arm_group_label>CPX-351 Salvage Therapy and Transplant</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabbit Anti-Human T-Lymphocyte Globulin</intervention_name>
    <description>Rabbit ATG (rATG)-thymoglobulin 4.5 mg/kg (1.5 mg/kg/day x 3 days)</description>
    <arm_group_label>CPX-351 Salvage Therapy and Transplant</arm_group_label>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Haplo-Cord Stem Cell Transplantation</intervention_name>
    <description>Allogeneic stem cell transplantation using a haploidentical donor and umbilical cord blood unit.</description>
    <arm_group_label>CPX-351 Salvage Therapy and Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must have refractory or relapsed Acute Myeloid Leukemia (AML) according to
             previously established criteria:

               1. Primary induction failure (PIF) after ≥ 2 cycles of chemotherapy

               2. First relapse

               3. Relapse refractory to salvage chemotherapy

               4. Second or subsequent relapse

          2. Subjects with Myelodysplastic Syndrome (MDS):

             (a) Either Refractory Anemia with Excess Blasts I or Refractory Anemia with Excess
             Blasts II (RAEB I or RAEB II)

          3. Karnofsky performance status ≥ 70

          4. Willing to participate as a research subject and sign an informed consent form

          5. Adequate physical function measured by:

               1. Cardiac: asymptomatic, or if symptomatic then Left Ventricular Ejection Fraction
                  (LVEF) at rest must be ≥ 45% and must improve with exercise

               2. Hepatic: ≤3 x upper limit of normal (ULN) alanine aminotransferase (ALT) and ≤
                  1.5 total serum bilirubin, unless liver is involved with the disease or there is
                  congenital benign hyperbilirubinemia

               3. Renal: serum creatinine within normal range, or if serum creatinine is outside
                  the normal range, then calculated creatinine clearance ≥ 60 ml/min

               4. Pulmonary: asymptomatic, or if symptomatic, diffusing capacity of the lungs for
                  carbon monoxide (DLCO) ≥ 45% of predicted (corrected for hemoglobin)

          6. If subject has prior malignancy, must be without any evidence of disease of that prior
             malignancy for at least 2 years (excludes skin cancers that may have been excised
             within that 2 year period).

        Exclusion Criteria:

          1. Serious active or uncontrolled infection or medical condition

          2. Women who are pregnant or breast feeding. Women of childbearing age must use adequate
             contraception and have a negative pregnancy test.

          3. Prior daunorubicin therapy with a cumulative dose of more than 368 mg/m2 or equivalent

          4. Other systemic anticancer therapy or ongoing clinically relevant toxicities from such
             therapy (at discretion of the investigator)

          5. History of and/or current evidence of myocardial impairment (e.g. cardiomyopathy,
             ischemic heart disease, significant valvular dysfunction, hypertensive heart disease,
             congestive heart failure), resulting in heart failure by New York Heart Association
             Class III or IV staging.

          6. Subjects with Wilson disease or other Copper-related disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Usama Gergis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Bourle, RN</last_name>
    <phone>212-746-2844</phone>
    <email>jeb9097@med.cornell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Usama Gergis, MD</last_name>
    <phone>646-962-7950</phone>
    <email>usg2001@med.cornell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Bourke, RN</last_name>
      <phone>212-746-2844</phone>
      <email>jeb9097@med.cornell.edi</email>
    </contact>
    <contact_backup>
      <last_name>Usama Gergis, MD</last_name>
      <phone>646-962-7950</phone>
      <email>usg2001@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Usama Gergis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Koen van Besien, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tsiporah Shore, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastian Mayer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2017</study_first_submitted>
  <study_first_submitted_qc>January 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

